Logo image of MYGN

MYRIAD GENETICS INC (MYGN) Stock Fundamental Analysis

NASDAQ:MYGN - Nasdaq - US62855J1043 - Common Stock - Currency: USD

5.67  +1.8 (+46.51%)

Premarket: 5.61 -0.06 (-1.06%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to MYGN. MYGN was compared to 551 industry peers in the Biotechnology industry. MYGN may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, MYGN is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

MYGN had positive earnings in the past year.
MYGN had a negative operating cash flow in the past year.
MYGN had negative earnings in each of the past 5 years.
In multiple years MYGN reported negative operating cash flow during the last 5 years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M -200M

1.2 Ratios

MYGN's Return On Assets of -12.39% is amongst the best of the industry. MYGN outperforms 82.58% of its industry peers.
With an excellent Return On Equity value of -18.16%, MYGN belongs to the best of the industry, outperforming 86.39% of the companies in the same industry.
Industry RankSector Rank
ROA -12.39%
ROE -18.16%
ROIC N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

The Gross Margin of MYGN (69.89%) is better than 81.85% of its industry peers.
MYGN's Gross Margin has declined in the last couple of years.
MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.89%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60

More info and screens

2

2. Health

2.1 Basic Checks

MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MYGN has been increased compared to 1 year ago.
Compared to 5 years ago, MYGN has more shares outstanding
Compared to 1 year ago, MYGN has a worse debt to assets ratio.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

Based on the Altman-Z score of 0.31, we must say that MYGN is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.31, MYGN is in the better half of the industry, outperforming 62.61% of the companies in the same industry.
MYGN has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
MYGN's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. MYGN is outperformed by 62.79% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z 0.31
ROIC/WACCN/A
WACC10.73%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 1.82 indicates that MYGN should not have too much problems paying its short term obligations.
The Current ratio of MYGN (1.82) is worse than 78.40% of its industry peers.
A Quick Ratio of 1.65 indicates that MYGN should not have too much problems paying its short term obligations.
MYGN has a Quick ratio of 1.65. This is in the lower half of the industry: MYGN underperforms 79.67% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.65
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

6

3. Growth

3.1 Past

MYGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 120.00%, which is quite impressive.
Measured over the past years, MYGN shows a very strong growth in Earnings Per Share. The EPS has been growing by 86.63% on average per year.
The Revenue has grown by 11.21% in the past year. This is quite good.
MYGN shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.32% yearly.
EPS 1Y (TTM)120%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)11.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%0.76%

3.2 Future

MYGN is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 36.32% yearly.
MYGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 4.75% yearly.
EPS Next Y-107.85%
EPS Next 2Y9.45%
EPS Next 3Y36.61%
EPS Next 5Y36.32%
Revenue Next Year-3.42%
Revenue Next 2Y1.49%
Revenue Next 3Y3.35%
Revenue Next 5Y4.75%

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 0.5 -0.5 1 1.5

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 51.55, which means the current valuation is very expensive for MYGN.
Based on the Price/Earnings ratio, MYGN is valued cheaper than 92.92% of the companies in the same industry.
MYGN's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.99.
A Price/Forward Earnings ratio of 36.41 indicates a quite expensive valuation of MYGN.
Based on the Price/Forward Earnings ratio, MYGN is valued cheaper than 91.47% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 36.36. MYGN is around the same levels.
Industry RankSector Rank
PE 51.55
Fwd PE 36.41
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

MYGN's earnings are expected to grow with 36.61% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y9.45%
EPS Next 3Y36.61%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MYGN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MYRIAD GENETICS INC

NASDAQ:MYGN (8/6/2025, 8:00:02 PM)

Premarket: 5.61 -0.06 (-1.06%)

5.67

+1.8 (+46.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners103.92%
Inst Owner Change0.68%
Ins Owners2.55%
Ins Owner Change14.34%
Market Cap522.66M
Analysts53.33
Price Target7.34 (29.45%)
Short Float %8.48%
Short Ratio4.4
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)101.18%
Min EPS beat(2)-2.9%
Max EPS beat(2)205.26%
EPS beat(4)3
Avg EPS beat(4)198.46%
Min EPS beat(4)-2.9%
Max EPS beat(4)500.81%
EPS beat(8)6
Avg EPS beat(8)133.36%
EPS beat(12)9
Avg EPS beat(12)102.73%
EPS beat(16)13
Avg EPS beat(16)96.48%
Revenue beat(2)0
Avg Revenue beat(2)-1.6%
Min Revenue beat(2)-2.43%
Max Revenue beat(2)-0.76%
Revenue beat(4)2
Avg Revenue beat(4)0.1%
Min Revenue beat(4)-2.43%
Max Revenue beat(4)2.44%
Revenue beat(8)4
Avg Revenue beat(8)0.5%
Revenue beat(12)7
Avg Revenue beat(12)0.25%
Revenue beat(16)9
Avg Revenue beat(16)1.25%
PT rev (1m)0%
PT rev (3m)-51.02%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-112.93%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)-4.18%
Valuation
Industry RankSector Rank
PE 51.55
Fwd PE 36.41
P/S 0.62
P/FCF N/A
P/OCF N/A
P/B 0.75
P/tB 3.43
EV/EBITDA N/A
EPS(TTM)0.11
EY1.94%
EPS(NY)0.16
Fwd EY2.75%
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS9.09
BVpS7.61
TBVpS1.65
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -12.39%
ROE -18.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.89%
FCFM N/A
ROA(3y)-14.9%
ROA(5y)-12.19%
ROE(3y)-21.47%
ROE(5y)-17.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.7%
GM growth 5Y-1.76%
F-Score5
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 48.53%
Cap/Sales 3.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.65
Altman-Z 0.31
F-Score5
WACC10.73%
ROIC/WACCN/A
Cap/Depr(3y)84.3%
Cap/Depr(5y)59.15%
Cap/Sales(3y)6.65%
Cap/Sales(5y)4.83%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)120%
EPS 3Y86.63%
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-107.85%
EPS Next 2Y9.45%
EPS Next 3Y36.61%
EPS Next 5Y36.32%
Revenue 1Y (TTM)11.21%
Revenue growth 3Y6.64%
Revenue growth 5Y-0.32%
Sales Q2Q%0.76%
Revenue Next Year-3.42%
Revenue Next 2Y1.49%
Revenue Next 3Y3.35%
Revenue Next 5Y4.75%
EBIT growth 1Y34.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-1.36%
EBIT Next 3Y46.98%
EBIT Next 5Y46.13%
FCF growth 1Y79.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y92.16%
OCF growth 3YN/A
OCF growth 5YN/A